Literature DB >> 12095460

Peripheral and central sensitization in fibromyalgia: pathogenetic role.

Roland Staud1, Michael L Smitherman.   

Abstract

Characteristic symptoms of fibromyalgia syndrome include widespread pain, fatigue, sleep abnormalities, and distress. Patients with fibromyalgia show psychophysical evidence of mechanical, thermal, and electrical hyperalgesia. Peripheral and central abnormalities of nociception have been described in fibromyalgia. Important nociceptor systems in the skin and muscles seem to undergo profound changes in patients with fibromyalgia through unknown mechanisms. They include sensitization of vanilloid receptor, acid-sensing ion channel receptors, and purino-receptors. Tissue mediators of inflammation and nerve growth factors can excite these receptors and cause extensive changes in pain sensitivity, but patients with fibromyalgia lack consistent evidence for inflammatory soft tissue abnormalities. Therefore, recent investigations have focused on central nervous system mechanisms of pain in fibromyalgia.

Entities:  

Mesh:

Year:  2002        PMID: 12095460     DOI: 10.1007/s11916-002-0046-1

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  89 in total

1.  Cortical and subcortical localization of response to pain in man using positron emission tomography.

Authors:  A K Jones; W D Brown; K J Friston; L Y Qi; R S Frackowiak
Journal:  Proc Biol Sci       Date:  1991-04-22       Impact factor: 5.349

Review 2.  P2 purinoceptors: historical perspective and classification.

Authors:  G Burnstock
Journal:  Ciba Found Symp       Date:  1996

3.  Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis.

Authors:  Henning Vaerøy; Robert Helle; Øystein Førre; Erik Kåss; Lars Terenius
Journal:  Pain       Date:  1988-01       Impact factor: 6.961

Review 4.  Transcriptional and posttranslational plasticity and the generation of inflammatory pain.

Authors:  C J Woolf; M Costigan
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

5.  Neurotrophins: peripherally and centrally acting modulators of tactile stimulus-induced inflammatory pain hypersensitivity.

Authors:  R J Mannion; M Costigan; I Decosterd; F Amaya; Q P Ma; J C Holstege; R R Ji; A Acheson; R M Lindsay; G A Wilkinson; C J Woolf
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

6.  Activation of protein kinase C augments peptide release from rat sensory neurons.

Authors:  L A Barber; M R Vasko
Journal:  J Neurochem       Date:  1996-07       Impact factor: 5.372

7.  Cerebrospinal fluid levels of substance P and calcitonin-gene-related peptide: correlation with sural nerve levels and neuropathic signs in sensory diabetic polyneuropathy.

Authors:  C Tsigos; L T Diemel; A White; D R Tomlinson; R J Young
Journal:  Clin Sci (Lond)       Date:  1993-03       Impact factor: 6.124

8.  Effect of bradykinin antagonists on bradykinin-induced plasma extravasation, venoconstriction, prostaglandin E2 release, nociceptor stimulation and contraction of the iris sphincter muscle in the rabbit.

Authors:  T Griesbacher; F Lembeck
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

Review 9.  Spinal mechanisms of acute and persistent pain.

Authors:  A I Basbaum
Journal:  Reg Anesth Pain Med       Date:  1999 Jan-Feb       Impact factor: 6.288

Review 10.  Oxidative stress, glutamate, and neurodegenerative disorders.

Authors:  J T Coyle; P Puttfarcken
Journal:  Science       Date:  1993-10-29       Impact factor: 47.728

View more
  36 in total

1.  A population-based twin study of functional somatic syndromes.

Authors:  K Kato; P F Sullivan; B Evengård; N L Pedersen
Journal:  Psychol Med       Date:  2008-06-26       Impact factor: 7.723

Review 2.  Role of functional brain imaging in understanding rheumatic pain.

Authors:  Anthony K P Jones; Nathan T M Huneke; Donna M Lloyd; Chris A Brown; Alison Watson
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

3.  Fibromyalgia: From treatment to rehabilitation.

Authors:  Marta Imamura; David A Cassius; Felipe Fregni
Journal:  Eur J Pain       Date:  2009-11-01       Impact factor: 3.931

4.  Chronic pain in patients with the hypermobility type of Ehlers-Danlos syndrome: evidence for generalized hyperalgesia.

Authors:  Lies Rombaut; Mark Scheper; Inge De Wandele; Janneke De Vries; Mira Meeus; Fransiska Malfait; Raoul Engelbert; Patrick Calders
Journal:  Clin Rheumatol       Date:  2014-02-04       Impact factor: 2.980

Review 5.  Coordinate-based meta-analysis of experimentally induced and chronic persistent neuropathic pain.

Authors:  Ulrike Friebel; Simon B Eickhoff; Martin Lotze
Journal:  Neuroimage       Date:  2011-07-20       Impact factor: 6.556

Review 6.  Fibromyalgia, fatigue, and headache disorders.

Authors:  Mario F P Peres
Journal:  Curr Neurol Neurosci Rep       Date:  2003-03       Impact factor: 5.081

7.  A brain-derived neurotrophic factor polymorphism Val66Met identifies fibromyalgia syndrome subgroup with higher body mass index and C-reactive protein.

Authors:  Yangming Xiao; I Jon Russell; Ya-Guang Liu
Journal:  Rheumatol Int       Date:  2011-07-21       Impact factor: 2.631

8.  Evidence for generalized hyperalgesia in chronic fatigue syndrome: a case control study.

Authors:  Mira Meeus; Jo Nijs; Sven Huybrechts; Steven Truijen
Journal:  Clin Rheumatol       Date:  2010-04       Impact factor: 2.980

9.  Dysfunctional pain inhibition in patients with chronic whiplash-associated disorders: an experimental study.

Authors:  Liesbeth Daenen; Jo Nijs; Nathalie Roussel; Kristien Wouters; Michel Van Loo; Patrick Cras
Journal:  Clin Rheumatol       Date:  2012-09-16       Impact factor: 2.980

Review 10.  Rehabilitation of chronic whiplash: treatment of cervical dysfunctions or chronic pain syndrome?

Authors:  Jo Nijs; Jessica Van Oosterwijck; Willem De Hertogh
Journal:  Clin Rheumatol       Date:  2009-01-22       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.